Prospective Study on Paclitaxel Combined with Oxaliplatin and 5-fluorouracil in the Treatment of Advanced Gastric Cancer / 中国药房

ABSTRACT

OBJECTIVE:To study the clinical efficacy and adverse drug reactions (ADR) of paclitaxel combined with oxaliplatin and 5-fluorouracil (5-Fu) in the treatment of advanced gastric cancer.METHODS:31 patients with advanced gastric cancer were treated with paclitaxel 175 mg?m-2 (i.v.) for 3 hours followed by oxaliplatin 85 mg?m-2 on the first day and 24 hour infusion of 5-Fu (500 mg?m-2,first to fifth day) every 3 weeks.Total effective rate,survival duration and ADR were observed.RESULTS:The total effective rate was 38.7% (12/31),including complete remission of 9.7% (3/31),partial remission of 29.0%(9/31),steady progress (SD) of 41.9% (13/31) and promotion progress (PD) of 19.4% (6/31).The median time to progression (TTP) was 5.9 months and median survival time (MST) was 10.7 months.The total response rates were 70% for newly diagnosis patients and 23.8% for recurrence patients.The main ADR were neurotoxicity (89.1%),leukopenia (82.6%),nausea/vomiting (72.8%) and alopecia (66.3%).None of chemotherapy-related death occurred.CONCLUSION:Paclitaxel combined with oxaliplatin and 5-Fu POF regimen appears to be effective and tolerated in the treatment of advanced gastric cancer.